Big pharma groups are snapping up biotechs at a record pace as they race to bolster their drug pipelines, spend windfalls from blockbuster medicines and capitalise on lighter-touch regulation under the Trump administration. The number of biotechs acquired for at least $US1 billion ($1.4 billion) this year has reached 37, already surpassing the annual record of 35 set last year, according to US investment firm Stifel. Executives and bankers say the most powerful catalyst for the deal fever is what is known as the “patent cliff”, a recurring feature of the industry in which drugmakers lose the exclusivity on prized medicines, paving the way for generic manufacturers to sweep in and produce cheaper versions.
Read the full article: Biotech Deals Surge to Record as Fear of Missing Out Grips Big Pharma //
Source: https://www.afr.com/companies/healthcare-and-fitness/biotech-deals-surge-to-record-as-fear-of-missing-out-grips-big-pharma-20260721-p60hb9